Provisional BCS Classification

This Biopharmaceutics Classification (BCS) is a provisional classification based on readily available literature solubilities and human permeabilities or estimated LogP or ClogP values relative to metoprolol. For a more detailed discussion of the approach taken in the database see the following references:

Young Hoon Kim, Chandrasekharan Ramachandran, Gordon M. Crippen, Toshihide Takagi, Marival Bermejo, and Gordon L. Amidon, In Silico Approaches to Prediction of Permeability, Solubility, and BCS Class: Provisional Classificatio nof the Top-selling Immediate-Release Oral Drug Products in the United States, Great Britain, Spain, Japan, and South Korea, Molecular Pharmaceutics, (submitted)

Toshihide Takagi, Chandrasekharan Ramachandran, Marival Bermejo, Shinji Yamashita, John M. Hilfinger and Gordon L. Amidon, Provisional Biopharmaceutical Classification of Oral Drugs in the United States, Europe and Japan, Molecular Pharmaceutics, (submitted)

N.A. Kasim, M. WHitehouse, C. Ramachandran, M. Bermejo, H. Lennernas, A.S. Hussain, H.E. Junginger, S.A. Stavchansky, K.K. Midha, V.P. Shah and G.L. Amidon, Molecular Properties of WHO Essential Drugs and Provisional Biopharmacetucial Classification, Molecular Pharmaceutics, 1, 85 (2004).

Use of this database is at the discretion of the user. TSRL, Inc. is not responsible for any misuse or misrepresentation of this database.